Other

DescriptionStatement levelStatement and Statistics
01 Stereotactic anterior capsulotomy vs. cingulotomy
01 CPRS @ 3 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing psychopathological symptoms as measured by the CPRS (N = 1; n = 4; SMD = -5.79; 95% CI, -38.62 to 27.03). I
02 CPRS @ 6 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing psychopathological symptoms as measured by the CPRS (N = 1; n = 4; SMD = -0.3; 95% CI, -2.89 to 2.29). I
03 CPRS @ 12 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing psychopathological symptoms as measured by the CPRS (N = 1; n = 4; SMD = 0.46; 95% CI, -2.78 to 3.7). I
04 HAM-D @ 3 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing depressive symptoms as measured by the HAM-D (N = 1; n = 4; SMD = 0.19; 95% CI, -2.05 to 2.43). I
05 HAM-D @ 6 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing depressive symptoms as measured by the HAM-D (N = 1; n = 4; SMD = 0; 95% CI, -1.96 to 1.96). I
06 HAM-D @ 12 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing depressive symptoms as measured by the HAM-D (N = 1; n = 4; SMD = 0.48; 95% CI, -2.89 to 3.86). I
07 HAM-A @ 3 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing anxiety symptoms as measured by the HAM-A (N = 1; n = 4; SMD = 0.5; 95% CI, -2.94 to 3.95). I
08 HAM-A @ 6 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing anxiety symptoms as measured by the HAM-A (N = 1; n = 4; SMD = 0.38; 95% CI, -2.54 to 3.31). I
09 HAM-A @ 12 months: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between capsulotomy and cingulotomy on reducing anxiety symptoms as measured by the HAM-A (N = 1; n = 4; SMD = 0.47; 95% CI, -2.84 to 3.79). I
02 Repetitive transcranial magnetic stimulation: active vs. placebo
01 Adverse effectss4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between active RTMS and placebo RTMS on the likelihood of reporting adverse effects (N = 1; n = 18; RR = 2.45; 95% CI, 0.11 to 53.25). I
02 Non-responders (Y-BOCS 40%)s4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between active RTMS and placebo RTMS on the likelihood of response, defined as a reduction of 40% or greater on the Y-BOCS, (N = 1; n = 18; RR = 0.91; 95% CI, 0.61 to 1.37). I
03 Y-BOCS: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between active RTMS and placebo RTMS on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 18; SMD = -0.45; 95% CI, -1.39 to 0.5). I
04 HAM-D: change scores4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between active RTMS and placebo RTMS on reducing depressive symptoms as measured by the HAM-D (N = 1; n = 18; SMD = -0.17; 95% CI, -1.1 to 0.76). I
03 Repetitive transcranial magnetic stimulation: right vs. left
01 Y-BOCS @ post-treatment
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 12; SMD = 0.03; 95% CI, -1.1 to 1.16). I
02 BDI @ post-treatment
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing depressive symptoms as measured by the BDI (N = 1; n = 12; SMD = 0.48; 95% CI, -0.67 to 1.64). I
03 MADRS @ post-treatment
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing depressive symptoms as measured by the MADRS (N = 1; n = 12; SMD = 0.95; 95% CI, -0.27 to 2.18). I
04 STAI-S @ post-treatment
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing anxiety symptoms as measured by the STAI-S (N = 1; n = 12; SMD = 0.04; 95% CI, -1.1 to 1.17). I
05 Y-BOCS @ 1 month follow-up
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 12; SMD = -0.64; 95% CI, -1.81 to 0.54). I
06 BDI @ 1 month follow-up
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing depressive symptoms as measured by the BDI (N = 1; n = 12; SMD = 0.06; 95% CI, -1.07 to 1.19). I
07 MADRS @ 1 month follow-up
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing depressive symptoms as measured by the MADRS (N = 1; n = 12; SMD = 0.67; 95% CI, -0.51 to 1.85). I
08 STAI-S @ 1 month follow-up
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on reducing anxiety symptoms as measured by the STAI-S (N = 1; n = 12; SMD = -0.05; 95% CI, -1.18 to 1.08). I
09 Non-responders (Y-BOCS 40%) @ 1 month follow-up
01 Right prefrontal vs. left prefrontals4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between right prefrontal RTMS and left prefrontal RTMS on the likelihood of response, defined as a reduction of 40% or greater on the Y-BOCS, (N = 1; n = 12; RR = 1; 95% CI, 0.2 to 4.95). I
04 Plasma exchange vs. IV immunoglobulin vs. placebo (child/adolescent: at 1 month after start of treatment)
01 Adverse effects
01 Plasma exchange vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and placebo on the likelihood of reporting adverse effects (N = 1; n = 20; RR = 3.5; 95% CI, 0.95 to 12.9). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on the likelihood of reporting adverse effects (N = 1; n = 20; RR = 3; 95% CI, 0.79 to 11.44). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on the likelihood of reporting adverse effects (N = 1; n = 20; RR = 1.17; 95% CI, 0.61 to 2.23). I
02 Leaving study early
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on the likelihood of leaving the study early (N = 1; n = 20; RR = 3; 95% CI, 0.14 to 65.9). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on the likelihood of leaving the study early (N = 1; n = 20; RR = 0.33; 95% CI, 0.02 to 7.32). I
03 Y-BOCS*
01 Plasma exchange vs. placebos2xThere is limited evidence suggesting a difference favouring plasma exchange over placebo on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 12; SMD = -2.24; 95% CI, -3.83 to -0.66). I
02 IV immunoglobulin vs. placebos2xThere is limited evidence suggesting a difference favouring IV immunoglobulin over placebo on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 13; SMD = -1.57; 95% CI, -2.88 to -0.26). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 11; SMD = 0.04; 95% CI, -1.15 to 1.23). I
04 NIMH-Global Severity*
01 Plasma exchange vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and placebo on reducing global severity of symptoms as measured by the NIMH-Global Severity scale (N = 1; n = 12; SMD = -1.15; 95% CI, -2.43 to 0.13). I
02 IV immunoglobulin vs. placebos2xThere is limited evidence suggesting a difference favouring IV immunoglobulin over placebo on reducing global severity of symptoms as measured by the NIMH-Global Severity scale (N = 1; n = 13; SMD = -1.26; 95% CI, -2.5 to -0.03). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing global severity of symptoms as measured by the NIMH-Global Severity scale (N = 1; n = 11; SMD = 0; 95% CI, -1.19 to 1.19). I
05 CGI-Symptom Severity*
01 Plasma exchange vs. placebos2xThere is limited evidence suggesting a difference favouring plasma exchange over placebo on reducing symptom severity as measured by the CGI-Symptom Severity scale (N = 1; n = 12; SMD = -1.43; 95% CI, -2.78 to -0.09). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on reducing symptom severity as measured by the CGI-Symptom Severity scale (N = 1; n = 13; SMD = -1.06; 95% CI, -2.25 to 0.14). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing symptom severity as measured by the CGI-Symptom Severity scale (N = 1; n = 11; SMD = -0.26; 95% CI, -1.46 to 0.93). I
06 Global Assessment Scale*
01 Plasma exchange vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and placebo on improving global functioning as measured by the Global Assessment Scale (N = 1; n = 12; SMD = -0.93; 95% CI, -2.16 to 0.31). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on improving global functioning as measured by the Global Assessment Scale (N = 1; n = 13; SMD = -0.94; 95% CI, -2.11 to 0.23). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on improving global functioning as measured by the Global Assessment Scale (N = 1; n = 11; SMD = -0.05; 95% CI, -1.23 to 1.14). I
07 NIMH-Anxiety*
01 Plasma exchange vs. placebos2xThere is limited evidence suggesting a difference favouring plasma exchange over placebo on reducing anxiety symptoms as measured by the NIMH-Anxiety scale (N = 1; n = 12; SMD = -1.43; 95% CI, -2.77 to -0.09). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on reducing anxiety symptoms as measured by the NIMH-Anxiety scale (N = 1; n = 13; SMD = -1.12; 95% CI, -2.32 to 0.09). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing anxiety symptoms as measured by the NIMH-Anxiety scale (N = 1; n = 11; SMD = -0.56; 95% CI, -1.79 to 0.66). I
08 NIMH-Depression*
01 Plasma exchange vs. placebos2xThere is limited evidence suggesting a difference favouring plasma exchange over placebo on reducing depressive symptoms as measured by the NIMH-Depression scale (N = 1; n = 12; SMD = -1.62; 95% CI, -3.02 to -0.23). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on reducing depressive symptoms as measured by the NIMH-Depression scale (N = 1; n = 13; SMD = -1.14; 95% CI, -2.35 to 0.07). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing depressive symptoms as measured by the NIMH-Depression scale (N = 1; n = 11; SMD = -0.69; 95% CI, -1.93 to 0.55). I
09 NIMH-OC*
01 Plasma exchange vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and placebo on reducing obsessive-compulsive symptoms as measured by the NIMH-OC scale (N = 1; n = 12; SMD = -1.04; 95% CI, -2.29 to 0.22). I
02 IV immunoglobulin vs. placebos4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between IV immunoglobulin and placebo on reducing obsessive-compulsive symptoms as measured by the NIMH-OC scale (N = 1; n = 13; SMD = -1.08; 95% CI, -2.28 to 0.12). I
03 Plasma exchange vs. IV immunoglobulins4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing obsessive-compulsive symptoms as measured by the NIMH-OC scale (N = 1; n = 11; SMD = -0.05; 95% CI, -1.23 to 1.14). I
05 Plasma exchange vs. IV immunoglobulin (child/adolescent: at 1 year after start of treatment)
01 Leaving study earlys4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on the likelihood of leaving the study early (N = 1; n = 19; RR = 4.55; 95% CI, 0.25 to 83.7). I
02 Y-BOCS*s4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on reducing obsessive-compulsive symptoms as measured by the Y-BOCS (N = 1; n = 11; SMD = -0.24; 95% CI, -1.43 to 0.96). I
03 Global Assessment Scale*s4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between plasma exchange and IV immunoglobulin on improving global functioning as measured by the Global Assessment Scale (N = 1; n = 11; SMD = -0.95; 95% CI, -2.23 to 0.34). I

From: Appendix 18, Evidence statements

Cover of Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
NICE Clinical Guidelines, No. 31.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2006.
Copyright © 2006, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.